Business

Context Therapeutics pays USD 6.5m to buy out BioAtla CT-202 Nectin-4 CD3 obligations

Context Therapeutics (Nasdaq: CNTX) has paid USD 6.5 million to buy out all future milestone and royalty obligations on CT-202, its Nectin-4 x CD3 T cell engager, converting the original exclusive license from BioAtla (Nasdaq: BCAB) into a fully paid-up, non-terminable agreement. The amendment, announced May 18, 2026, closes out all remaining financial obligations to BioAtla under the original deal signed September 23, 2024, and arrives ahead of a Phase I trial initiation Context expects in Q3 2026.

The buyout is structured as two cash payments: USD 4.5 million paid at signing and a second USD 2.0 million due by August 1, 2026. The original license terms — including the specific milestone and royalty schedule that has now been extinguished — were not disclosed at the time of the 2024 agreement and remain undisclosed.

Deal context

CT-202 is a bispecific T cell engager targeting Nectin-4 on tumor cells and CD3 on cytotoxic T cells. The molecule is built on BioAtla's Conditionally Active Biologic (CAB) platform, which engineers antibodies to remain largely inactive at normal physiological pH (~7.4) and become active in the acidic tumor microenvironment (pH ~6.0–6.5). According to BioAtla's published platform description, this pH-dependent switching is driven by protonation of negatively charged residues that otherwise interfere with target binding — a reversible mechanism that, in preclinical models, has demonstrated differential binding ratios of roughly 9-fold to more than 175-fold between acidic and normal pH conditions.

Nectin-4 is a clinically validated oncology target: the ADC enfortumab vedotin targets the same antigen and carries US FDA approval in urothelial carcinoma. Context is pursuing CT-202 across bladder, breast, lung, and broader solid tumor indications. The company describes CT-202 as preferentially active within the tumor microenvironment, a design intended to reduce the on-target, off-tumor toxicities — including neuropathy and rash — associated with systemic Nectin-4 targeting. Context presented preclinical data on CT-202 at the American Association for Cancer Research Annual Meeting in April 2026. The Phase I trial record is listed on ClinicalTrials.gov as NCT07545122.

For Context, the transaction converts a contingent liability of unknown size into a fixed, capped cost. If CT-202 reaches commercialization, the economics of having eliminated royalties at this stage could be material. The trade-off is that Context assumes full development cost and risk with no ongoing BioAtla participation.

The AllSci BriefSystematic R&D and deal news. Daily.

The bispecific T cell engager space in solid tumors has attracted sustained licensing activity, though most deals at the pre-clinical or early clinical stage carry significantly larger headline values. A comparable amendment structure — AC Immune converting a milestone-bearing Tau collaboration with Lilly into revised economics — was announced in April 2026, illustrating that license restructurings ahead of key clinical inflection points are occurring across modalities, often driven by one party's need for balance sheet clarity rather than asset-specific reassessment.

The CAB platform itself has not yet generated a commercially approved product, though BA3011 and BA3021 — BioAtla's ADC programs built on the same conditional biology — have reached Phase II. CT-202 would be among the first CAB-based bispecific TCEs to enter human trials, making the Q3 2026 Phase I initiation a meaningful data point for the platform's broader clinical validation.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/


Spot something wrong? Report an issue with this article